Skip to main content

Table 1 Baseline characteristics of participants in first 4 weeks

From: Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

 

Treatment Group

memantine+sertraline (n = 35)

placebo+sertraline (n = 30)

P value

Mean±SD

Count (%)

Mean±SD

Count (%)

Age (years)

35.03±11.35

 

334.83±10.30

  

Gender

Female

 

27

(77.1%)

 

17

(56.7%)

0.07

Male

 

8

(22.9%)

 

13

(43.3%)

Education

Illiterate

 

0

(0.0%)

 

1

(3.3%)

0.30

Primary

 

1

(2.9%)

 

2

(6.7%)

Secondary

 

9

(25.7%)

 

5

(16.7%)

High school diploma

 

9

(25.7%)

 

13

(43.3%)

University Education

 

16 (45.7%)

 

9

(30.0%)

Marital status

Single

 

18 (51.4%)

 

11 (36.7%)

0.08

Married

 

14 (40.0%)

 

17

(56.7%)

Divorced

 

0

(0.0%)

 

2

(6.7%)

Separated

 

3

(8.6%)

 

0

(0.0%)

Employment

Employed

 

18

(51.4%)

 

18 (60.0%)

0.71

Unemployed

 

7 (20.0%)

 

4

(13.3%)

Housewife

 

10

(28.6%)

 

8

(26.7%)

Previous treatment

Yes

 

4

(11.4%)

 

2

(6.7%)

0.50

No

 

31

(88.6%)

 

28 (93.3%)

Y-BOCS score (week 0)

Total

27.88±5.65

 

30.11±5.79

 

0.12

Obsession

15.07±2.57

 

15.53±2.50

 

0.46

Compulsion

12.70±4.30

 

14.57±3.81

 

0.07

WCST score (week 0)

Error

22.89±9.85

 

22.09±10.63

 

0.80

Categories

3.36±1.77

 

3.90±1.86

 

0.35

Perseveration

6.15±5.54

 

7.88±9.02

 

0.47

  1. SD standard deviation, Y-BOCS Yale-Brown Obsessive-Compulsive Scale